vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $339.0M, roughly 1.0× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -12.9%, a 26.1% gap on every dollar of revenue. On growth, Walker & Dunlop, Inc. posted the faster year-over-year revenue change (-0.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
HAE vs WD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $340.0M |
| Net Profit | $44.7M | $-13.9M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | -17.2% |
| Net Margin | 13.2% | -12.9% |
| Revenue YoY | -2.7% | -0.4% |
| Net Profit YoY | 19.3% | -131.0% |
| EPS (diluted) | $0.95 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $340.0M | ||
| Q3 25 | $327.3M | $337.7M | ||
| Q2 25 | $321.4M | $319.2M | ||
| Q1 25 | $330.6M | $237.4M | ||
| Q4 24 | $348.5M | $341.5M | ||
| Q3 24 | $345.5M | $292.3M | ||
| Q2 24 | $336.2M | $270.7M | ||
| Q1 24 | — | $228.1M |
| Q4 25 | $44.7M | $-13.9M | ||
| Q3 25 | $38.7M | $33.5M | ||
| Q2 25 | $34.0M | $34.0M | ||
| Q1 25 | $58.0M | $2.8M | ||
| Q4 24 | $37.5M | $44.8M | ||
| Q3 24 | $33.8M | $28.8M | ||
| Q2 24 | $38.4M | $22.7M | ||
| Q1 24 | — | $11.9M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | -17.2% | ||
| Q3 25 | 17.9% | 13.6% | ||
| Q2 25 | 16.8% | 14.5% | ||
| Q1 25 | 21.6% | 2.2% | ||
| Q4 24 | 16.9% | 15.3% | ||
| Q3 24 | 15.0% | 12.8% | ||
| Q2 24 | 11.8% | 10.4% | ||
| Q1 24 | — | 6.0% |
| Q4 25 | 13.2% | -12.9% | ||
| Q3 25 | 11.8% | 9.9% | ||
| Q2 25 | 10.6% | 10.6% | ||
| Q1 25 | 17.5% | 1.2% | ||
| Q4 24 | 10.8% | 13.1% | ||
| Q3 24 | 9.8% | 9.9% | ||
| Q2 24 | 11.4% | 8.4% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | $0.95 | $-0.41 | ||
| Q3 25 | $0.81 | $0.98 | ||
| Q2 25 | $0.70 | $0.99 | ||
| Q1 25 | $1.17 | $0.08 | ||
| Q4 24 | $0.74 | $1.32 | ||
| Q3 24 | $0.66 | $0.85 | ||
| Q2 24 | $0.74 | $0.67 | ||
| Q1 24 | — | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $299.3M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $1.7B |
| Total Assets | $2.5B | $5.1B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $299.3M | ||
| Q3 25 | $296.4M | $274.8M | ||
| Q2 25 | $292.9M | $233.7M | ||
| Q1 25 | $306.8M | $181.0M | ||
| Q4 24 | $320.8M | $279.3M | ||
| Q3 24 | $299.3M | $179.8M | ||
| Q2 24 | $344.4M | $208.1M | ||
| Q1 24 | — | $216.5M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $1.7B | ||
| Q3 25 | $849.2M | $1.8B | ||
| Q2 25 | $882.3M | $1.8B | ||
| Q1 25 | $820.8M | $1.7B | ||
| Q4 24 | $906.9M | $1.7B | ||
| Q3 24 | $878.9M | $1.7B | ||
| Q2 24 | $905.4M | $1.7B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | $2.5B | $5.1B | ||
| Q3 25 | $2.4B | $5.8B | ||
| Q2 25 | $2.5B | $4.7B | ||
| Q1 25 | $2.5B | $4.5B | ||
| Q4 24 | $2.5B | $4.4B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.5B | $4.2B | ||
| Q1 24 | — | $3.8B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-664.3M |
| Free Cash FlowOCF − Capex | $87.2M | $-680.1M |
| FCF MarginFCF / Revenue | 25.7% | -200.0% |
| Capex IntensityCapex / Revenue | 1.9% | 4.6% |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $-664.3M | ||
| Q3 25 | $111.3M | $-948.1M | ||
| Q2 25 | $17.4M | $-238.5M | ||
| Q1 25 | $116.6M | $-281.1M | ||
| Q4 24 | $43.8M | $129.4M | ||
| Q3 24 | $48.8M | $-202.0M | ||
| Q2 24 | $-27.4M | $-237.8M | ||
| Q1 24 | — | $38.4M |
| Q4 25 | $87.2M | $-680.1M | ||
| Q3 25 | $106.3M | $-950.4M | ||
| Q2 25 | $13.6M | $-241.0M | ||
| Q1 25 | $100.9M | $-284.7M | ||
| Q4 24 | $35.2M | $116.4M | ||
| Q3 24 | $39.4M | $-204.0M | ||
| Q2 24 | $-33.1M | $-241.7M | ||
| Q1 24 | — | $35.2M |
| Q4 25 | 25.7% | -200.0% | ||
| Q3 25 | 32.5% | -281.5% | ||
| Q2 25 | 4.2% | -75.5% | ||
| Q1 25 | 30.5% | -120.0% | ||
| Q4 24 | 10.1% | 34.1% | ||
| Q3 24 | 11.4% | -69.8% | ||
| Q2 24 | -9.8% | -89.3% | ||
| Q1 24 | — | 15.4% |
| Q4 25 | 1.9% | 4.6% | ||
| Q3 25 | 1.5% | 0.7% | ||
| Q2 25 | 1.2% | 0.8% | ||
| Q1 25 | 4.7% | 1.5% | ||
| Q4 24 | 2.5% | 3.8% | ||
| Q3 24 | 2.7% | 0.7% | ||
| Q2 24 | 1.7% | 1.4% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | -28.34× | ||
| Q2 25 | 0.51× | -7.02× | ||
| Q1 25 | 2.01× | -102.07× | ||
| Q4 24 | 1.17× | 2.89× | ||
| Q3 24 | 1.44× | -7.01× | ||
| Q2 24 | -0.71× | -10.49× | ||
| Q1 24 | — | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WD
Segment breakdown not available.
